Effects of Omega-3 Polyunsaturated Fatty Acids to The Serum Level of Interleukin-8, Percentage of Forced Expiratory Volume in 1 Second (%FEV1), and COPD Assesment Test Scores in Stable COPD Patients

Nisfi Angriani, Suradi Suradi, Yusup Subagio


Backgorund: Cigarette smoke inhalation and the other exposure can cause of airway inflammatory and it was the most cause of chronic obstruction pulmonary desease (COPD) pathogenesis. The airway inflammatory will release cytokines proinflammation, one of them was interleukin (IL)-8. Omega-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effect and its can decrease cytokines production in COPD pathogenesis.
Methods: This study aimed to analyze effects of omega 3 PUFAs on serum IL-8, %FEV1, and CAT score in stable COPD patients. Clinical trials of experimental with pretest and posttest designs were conducted of 32 stable COPD patients came to clinic in Dr. Moewardi Hospital Surakarta from December 2016 until February 2017. Samples were taken by consecutive sampling. Subjects were divided into two groups include the treatment group (n=16) received standard COPD therapy omega 3 PUFA 600mg/day and the control group (n=16) received only standard COPD therapy for 28 days.
Results: There were significant difference (P=0.0001) towards decreased of serum IL-8 between treatment group (-3.56+5.32pg/ml) and control group (8.90+9.98pg/ml), increase difference were no significantly of %VEP1 value (P=0.473) between treatment group (7.02+7.17pg/ml) and control group (5.32+5.97pg/ml), decrease difference of CAT scores significantly (P=0.0001) between treatment group (-16.13+3.03pg/ml) and control group (-4.75+4.17pg/ml).
Conclusions: Omega-3 PUFA may decrease airway inflammation with decrease serum IL-8 level significantly, increase of %FEV1 no significantly and improve the clinical symptoms of stable COPD by decreased CAT scores significantly in stable COPD patients. (J Respir Indo. 2017; 37(4): 265-77)


IL-8 serum, Omega-3 PUFA, COPD stable, CAT scores, %FEV1

Full Text:



Global Initial for Chronic Obstructive Lung Disease (GOLD), 2017; Global Initial for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Portland: MCR Vision Inc; 2017. p.1-123.

Rosenberg SR, Kalhan R, Mannino D. Epidemiology of chronic obstructive pulmonary disease:Prevalence, morbidity, mortality, and risk factors. Seminars in Respiratory and Critical Care Medicine. 2015;36:457-69.

World Health Organisation (WHO). Burden of COPD. [cited on 2017 April 26th] Available from: http://www.who.int/respiratory/copd/burden/en/

Perhimpunan Dokter Paru Indonesia (PDPI). Penyakit Paru Obstruktif Kronik. Diagnosis dan Penatalaksanaan. Jakarta: Perhimpunan Dokter Paru Indonesia; 2016. p. 1-111.

Lim S, Lam DC, Muttalif AR,Yunus F, Wongtim, S, Lan LT. Impact of Chronic Obstructive Pulmonary Disease (COPD) in the Asia-Pacific Region: The EPIC Asia Population-Based Survey. Asia Pacific Family Medicine. 2015;14:1-11.

Devereux GS. Definition, epidemiology, and risk factors. In: Currie GP, editor. ABC of COPD. 1st ed. West Sussex: Wiley-Blackwell; 2006. p. 1142-498.

Rahman I. Reactive oxygen species and antioxidant therapeutic approaches In: Barnes PJ, Drazen JM, Rennard SI, Thomson NC, editors. Asthma and COPD. 2nd ed. San Diego: Elsevier Ltd; 2009. p. 293-312.

Calvacante AG, Bruin PF. The role of oxidative stress in COPD:current concepts and perspectives. J Bras Pneumol. 2009;35(12):1227-37.

Wood AM, Stockley RA. The genetic of chronic obstructive pulmonary disease. Respiratory Research. 2006;7:1-14.

Rennard SI, Barnes PJ. Pathogenesis of COPD. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC, editors. Asthma and COPD Basic Mechanism and Clinical Management. 1st ed. London: Elsevier Science Ltd; 2002. p. 361-79.

Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease. AM J Respir Cell Mol Biol. 2005;32:367-72.

Barnes PJ. Mediators of chronic obstructive pulmonary disease. The American Society for Pharmacology and Experimental Therapeutics. 2004;56(4):515-48.

Macnee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:258-66.

Chung KF, Adcock IM. Multifaceted mechanism in COPD: Inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334-56.

Larsson K. Aspect on pathophysiological mechanism in COPD. Journal of Internal Medicine. 2007;262:311-40.

Barnes JP. New antiinflammatory targets for COPD. Macmillan Publishers Limited. 2013(12):543-57.

Wise RA. Chronic obstructive pulmonary disease: chronical course and management. In: Fishman. 2008. P. 737-46.

Calder. Omega-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. The American Journal of Clinical Nutrition. 2006;83:1505-19.

Matsuyama W, Mitsuyama H, Watanabe M, Oonakahara K, Higashimo I, Osame M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest. 2005;128:3817-27.

Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, Schols AM. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005;60:376-82.

Toraldo DM, Nuccio FD, Scoditti E. Systemic inflammation in chronic obstructive pulmonary disease may diet play a therapeutic role. J Aller Ther. 2013;(2):2-12.

Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease, cellular and molecular mechanism. Cell Biochemistry and Biophysics. 2005;43:167-88.

Bruno MA, Penque D. Chronic obstructive pulmonary disease and proteomics a match for success. J Aller Ther. 2012:71-6.

Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respiratory Research. 2006;7(53):2-10.

Suradi. Pengaruh rokok pada penyakit paru obstruktif kronik (PPOK), tinjauan patogenesis, klinis dan sosial (Pidato Pengukuhan Guru Besar Pulmonologi dan Ilmu Kedokteran Respirasi Universitas sebelas Maret). Surakarta: Universitas Sebelas Maret; 2007.

Senior RM, Atkinson JJ. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman’s pulmonary diseases and disorders. 4th ed. New York: McGraw- Hill Inc; 2008. p. 707-27.

White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6 the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58:73-80.

Rotondo D, Earl CR, Laing KJ, Kaimakamis D. Inhibition of cytokine- stimulated thymic lymphocyte proliferation by fatty acids: the role of eicosanoids. Biochim Biophys Acta. 1994;2(1223):185-94.

Calder. Mechanisms of action of (n-3) fatty acids. The Journal of Nutrition. 2012;142:592-9.

Boutroos C, Samasundar C, Razzah A. Omega 3 fatty acids. Arch Surg. 2010;145(6):515-20.

Baratawidjaja KG. Sistem imun nonspesifik. In: Baratawidjaja KG, editor. Imunologi Dasar. 10th ed. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia; 2012. p. 57-93.

Shahar E, Folsom AR, Melnick SL, Tockman MS, Comstock GW, Gennaro V, et al. Dietary n-3 polyunsaturatedfatty acids and smoking related chronic obstructive pulmonary disease. N Engl J Med. 1994;331:228-33.

DOI: https://doi.org/10.36497/jri.v37i4.80


  • There are currently no refbacks.

Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License